Arbutus Biopharma Corp - 8-K Filing
Arbutus Biopharma reported Q1 2026 revenue of $179.1 million, driven by estimated license revenue from Genevant related to a litigation settlement with Moderna. The company received $178.7 million in upfront payment and has cash, cash equivalents, and marketable securities totaling $95.2 million as of March 31, 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ABUS